vs
BioNTech SE（BNTX）与HALOZYME THERAPEUTICS, INC.（HALO）财务数据对比。点击上方公司名可切换其他公司
BioNTech SE的季度营收约是HALOZYME THERAPEUTICS, INC.的3.4倍（$1.5B vs $451.8M）。BioNTech SE净利率更高（-1.9% vs -31.3%，领先29.5%）
BioNTech SE是总部位于德国美因茨的跨国生物技术企业，专注于免疫疗法及疫苗研发工作，核心研究方向覆盖肿瘤、传染性疾病等医疗领域，相关技术处于全球生物医药行业领先水平。
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
BNTX vs HALO — 直观对比
营收规模更大
BNTX
是对方的3.4倍
$451.8M
净利率更高
BNTX
高出29.5%
-31.3%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $451.8M |
| 净利润 | $-28.7M | $-141.6M |
| 毛利率 | — | 82.6% |
| 营业利润率 | -3.1% | -20.6% |
| 净利率 | -1.9% | -31.3% |
| 营收同比 | — | 51.6% |
| 净利润同比 | — | -203.3% |
| 每股收益（稀释后） | — | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNTXHALO
| Q4 25 | — | $451.8M | ||
| Q3 25 | $1.5B | $354.3M | ||
| Q2 25 | $260.8M | $325.7M | ||
| Q1 25 | $182.8M | $264.9M | ||
| Q4 24 | — | $298.0M | ||
| Q3 24 | $1.2B | $290.1M | ||
| Q2 24 | $128.7M | $231.4M | ||
| Q1 24 | $187.6M | $195.9M |
净利润BNTXHALO
| Q4 25 | — | $-141.6M | ||
| Q3 25 | $-28.7M | $175.2M | ||
| Q2 25 | $-386.6M | $165.2M | ||
| Q1 25 | $-415.8M | $118.1M | ||
| Q4 24 | — | $137.0M | ||
| Q3 24 | $198.1M | $137.0M | ||
| Q2 24 | — | $93.2M | ||
| Q1 24 | — | $76.8M |
毛利率BNTXHALO
| Q4 25 | — | 82.6% | ||
| Q3 25 | — | 84.4% | ||
| Q2 25 | — | 85.8% | ||
| Q1 25 | — | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 83.0% | ||
| Q2 24 | — | 82.9% | ||
| Q1 24 | — | 85.5% |
营业利润率BNTXHALO
| Q4 25 | — | -20.6% | ||
| Q3 25 | -3.1% | 61.5% | ||
| Q2 25 | -192.1% | 62.2% | ||
| Q1 25 | -292.2% | 53.4% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | 0.8% | 56.3% | ||
| Q2 24 | -750.7% | 50.7% | ||
| Q1 24 | -270.4% | 48.8% |
净利率BNTXHALO
| Q4 25 | — | -31.3% | ||
| Q3 25 | -1.9% | 49.5% | ||
| Q2 25 | -148.2% | 50.7% | ||
| Q1 25 | -227.5% | 44.6% | ||
| Q4 24 | — | 46.0% | ||
| Q3 24 | 15.9% | 47.2% | ||
| Q2 24 | — | 40.3% | ||
| Q1 24 | — | 39.2% |
每股收益（稀释后）BNTXHALO
| Q4 25 | — | $-1.13 | ||
| Q3 25 | — | $1.43 | ||
| Q2 25 | — | $1.33 | ||
| Q1 25 | — | $0.93 | ||
| Q4 24 | — | $1.06 | ||
| Q3 24 | — | $1.05 | ||
| Q2 24 | — | $0.72 | ||
| Q1 24 | — | $0.60 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $133.8M |
| 总债务越低越好 | — | $2.1B |
| 股东权益账面价值 | — | $48.8M |
| 总资产 | — | $2.5B |
| 负债/权益比越低杠杆越低 | — | 43.89× |
8季度趋势，按日历期对齐
现金及短期投资BNTXHALO
| Q4 25 | — | $133.8M | ||
| Q3 25 | — | $419.7M | ||
| Q2 25 | — | $61.9M | ||
| Q1 25 | — | $176.3M | ||
| Q4 24 | — | $115.8M | ||
| Q3 24 | — | $154.3M | ||
| Q2 24 | — | $187.9M | ||
| Q1 24 | — | $164.6M |
总债务BNTXHALO
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
股东权益BNTXHALO
| Q4 25 | — | $48.8M | ||
| Q3 25 | — | $503.9M | ||
| Q2 25 | — | $332.7M | ||
| Q1 25 | — | $482.3M | ||
| Q4 24 | — | $363.8M | ||
| Q3 24 | — | $452.7M | ||
| Q2 24 | — | $289.4M | ||
| Q1 24 | — | $177.8M |
总资产BNTXHALO
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.2B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.8B |
负债/权益比BNTXHALO
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $219.0M |
| 自由现金流经营现金流 - 资本支出 | — | $217.6M |
| 自由现金流率自由现金流/营收 | — | 48.2% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $644.6M |
8季度趋势，按日历期对齐
经营现金流BNTXHALO
| Q4 25 | — | $219.0M | ||
| Q3 25 | — | $178.6M | ||
| Q2 25 | — | $99.7M | ||
| Q1 25 | — | $154.2M | ||
| Q4 24 | — | $178.5M | ||
| Q3 24 | — | $115.4M | ||
| Q2 24 | — | $55.8M | ||
| Q1 24 | — | $129.4M |
自由现金流BNTXHALO
| Q4 25 | — | $217.6M | ||
| Q3 25 | — | $175.6M | ||
| Q2 25 | — | $98.1M | ||
| Q1 25 | — | $153.3M | ||
| Q4 24 | — | $175.4M | ||
| Q3 24 | — | $113.9M | ||
| Q2 24 | — | $53.2M | ||
| Q1 24 | — | $125.9M |
自由现金流率BNTXHALO
| Q4 25 | — | 48.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | — | 30.1% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 64.3% |
资本支出强度BNTXHALO
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.8% |
现金转化率BNTXHALO
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNTX
暂无分部数据
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
